Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denmark-based DanDrit Biotech has entered into collaboration with the University Hospital IRCCS 'San Martino' - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa to begin a Phase III adjuvant trial of MelCancerVac in patients with no evidence of disease (NED) stage IV colorectal cancer (CRC).
Subscribe to our email newsletter
The trial is designed to assess the efficacy of DanDrit’s vaccine MelCancerVac (MCV) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.
San Martino Hospital head of the Medical Oncology Unit Dr Alberto Sobrero is the principal investigator of the randomized multicenter trial.
DanDrit chief executive officer Dr Eric Leire said over the last year the company has focused its efforts on developing MCV for colorectal cancer patients.
"We intend to continue our efforts to develop a vaccine that we hope can ameliorate the scourge of colorectal cancer," Leire said.
DanDrit Biotech is a subsidiary of DanDrit Biotech USA, a biotechnology firm seeking to develop an approved vaccine for the treatment of colorectal cancer.